CHNA Performance — Loncar China BioPharma ETF
Data updated: 2023-11-14
CHNA returned −13.76% over one year to Aug 2023. The annualised 3-year return is −18.97%. The fund trailed its China Equity category average: $100 invested three years ago grew to $53, against $74 for the category, and to $86 over one year, against $92. Volatility over the past three years was 32.71% a year. In the 12 months to Aug 2023 the fund took in a net $458K, and assets reached $4.16M.
CHNA Growth of $100
What $100 invested in Loncar China BioPharma ETF grew to, compounded from monthly returns reported on SEC Form N-PORT, against the China Equity category average over the same months.
| Period | CHNA | Category average |
|---|---|---|
| 1 year (Sep 2022 – Aug 2023) | $86 | $92 |
| 3 years (Sep 2020 – Aug 2023) | $53 | $74 |
| Since data start (Mar 2020 – Aug 2023) | $68 | $92 |
CHNA Trailing Returns
Total returns to Aug 2023, from SEC N-PORT.
| Period | Total return |
|---|---|
| 1 year | −13.76% |
| 3 years (annualised) | −18.97% |
CHNA Annual Returns
Calendar-year total returns of Loncar China BioPharma ETF, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2023 (Jan–Aug) | −21.34% |
| 2022 | −27.99% |
| 2021 | −9.42% |
| 2020 (Mar–Dec) | +32.25% |
CHNA Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 | +9.8% | −9.1% | −7.2% | +3.3% | −10.0% | −2.3% | +4.1% | −10.1% | — | — | — | — |
| 2022 | −17.7% | +2.3% | −7.3% | −10.5% | −2.9% | +12.0% | −9.3% | −4.7% | −18.6% | +1.1% | +24.8% | +6.8% |
| 2021 | +11.1% | +2.8% | −2.3% | +12.4% | +8.9% | +5.8% | −12.5% | −8.1% | −1.8% | −9.9% | −0.7% | −11.0% |
| 2020 | — | — | −8.2% | +11.6% | +4.6% | +14.3% | +5.1% | −0.9% | −4.5% | −2.9% | +2.5% | +9.0% |
CHNA Risk
Risk measures from monthly returns over Sep 2020 – Aug 2023.
- 3-year volatility (annualised): 32.71%
- 3-year Sharpe ratio: -0.72 (vs 4.5% risk-free rate)
- Best month: +24.83% (Nov 2022)
- Worst month: −18.65% (Sep 2022)
CHNA Fund Flows
Monthly money in and out of Loncar China BioPharma ETF, from SEC Form N-PORT.
- 12-month net flow: $458K
- 12-month gross sales (incl. reinvestments): $0
- Sales ÷ redemptions: -0.00×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Aug 2023 | $0 | $0 | $0 |
| Jul 2023 | $0 | $0 | $0 |
| Jun 2023 | $0 | $0 | $0 |
| May 2023 | $0 | $0 | $0 |
| Apr 2023 | $0 | $0 | $0 |
| Mar 2023 | $0 | −$458K | $458K |
| Feb 2023 | $0 | $0 | $0 |
| Jan 2023 | $0 | $0 | $0 |
| Dec 2022 | $0 | $0 | $0 |
| Nov 2022 | $0 | $0 | $0 |
| Oct 2022 | $0 | $0 | $0 |
| Sep 2022 | $0 | $0 | $0 |
CHNA Assets Under Management
Net assets of Loncar China BioPharma ETF by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2023-08-31 | $4.16M |
| 2023-05-31 | $4.55M |
| 2023-02-28 | $5.76M |
| 2022-11-30 | $5.40M |
| 2022-08-31 | $5.26M |
| 2022-05-31 | $5.43M |
| 2022-02-28 | $6.74M |
| 2021-11-30 | $11.74M |
| 2021-08-31 | $15.29M |
| 2021-05-31 | $17.98M |
| 2021-02-28 | $15.04M |
| 2020-11-30 | $11.39M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.